Mitchell Starr
Biographic Data
| ID | 7449834 |
|---|---|
| NAME | Mitchell Starr |
| GIVEN NAMES | Mitchell |
| FAMILY NAME | Starr |
| SIGNATURE | STARR M |
| AFFILIATIONS | St Vincent's Hospital Melbourne |
| ORCID | 0000-0001-9521-7496 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey
The temporal decline in HCV Ab prevalence appears related to reduced sensitivity of DBS HCV Ab detection with viral clearance following treatment. Since 2016, HCV treatment uptake has increased markedly including among people who inject drugs. In this context, continuing to monitor HCV Ab prevalence by DBS testing is problematic, with a shift to surveillance of active infection the most relevant to guide policy and practice in this setting
Concordance between self‐reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia
Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia
No prominent works on this page.
Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia
Concordance between self‐reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia
Utilising integrated bio-behavioural surveillance (IBBS) to investigate declining hepatitis C antibody prevalence among people who inject drugs in the Australian Needle and Syringe Program Survey
The temporal decline in HCV Ab prevalence appears related to reduced sensitivity of DBS HCV Ab detection with viral clearance following treatment. Since 2016, HCV treatment uptake has increased markedly including among people who inject drugs. In this context, continuing to monitor HCV Ab prevalence by DBS testing is problematic, with a shift to surveillance of active infection the most relevant to guide policy and practice in this setting
Hepatitis C (3 works) · Hepatitis C virus research (3 works) · HIV, Drug Use, Sexual Risk (3 works) · Medicine (3 works) · Environmental health (2 works) · Hepatitis B Virus Studies (2 works) · Hepatitis C virus (2 works) · Internal Medicine (2 works) · Psychiatry (2 works) · Syringe (2 works)